Biosimilar Medicines Market Review 2023

Report that provides an overview on the different policies that are currently in place for biosimilar medicines in Europe


Biosimilar Medicines Today

Biosimilar medicines were invented in Europe 20 years ago to address the pressing need for better access to biopharmaceuticals in Europe. For example, a recent study demonstrated the inequity in access to biologic medicines for treatment of rheumatoid arthritis because lower income countries in Europe cannot afford such therapies. However even within high-income countries such as Germany and the UK, only 10-14% of patients with rheumatoid arthritis received treatment with biologic medicines. Considerable benefit awaits those patients who will gain access to treatment with biologic medicines in both low and high income EU countries thanks to the arrival of biosimilar medicines competition.

Through sophisticated new technology, our industry was able to deliver a global first with the first biosimilar medicine approved in 2006. Since that time, our industry has continued to invest substantially in new innovation, bringing the total number of biosimilar medicines available today on the European market to 20.

Read more

Our 5 Pillars

Biosimilar medicines improve access to indispensable pillars of modern treatment for millions of patients and bring better value for healthcare spending.

The biosimilar medicines industry delivers sustainability for healthcare systems and is a key partner for stakeholders.

Read more

What's new

POLITICO – Everything you wanted to know about the EU’s pharma reform (but were too afraid to ask)

Read more

Did you know?

Since 2006, biosimilar medicines have generated more than 400 million patient days of clinical experience.


19th Biosimilar Medicines Conference
19th Biosimilar Medicines Conference
25-26 MAY 2023
Patient Workshop
Patient Workshop
24 MAY 2023
2nd Bioequivalence Workshope
2nd Bioequivalence Workshop
26 APRIL 2023

View all